Complete the form to instantly download the CeleCor Backgrounder

×

    *Indicates required field

    Clinical Development

    Study milestones

    Q4 2019

    Q4 2019

    Phase 1 study completed

    A randomized study of 14 healthy volunteers and 30 patients with stable coronary artery disease taking aspirin showed that zalunfiban administered subcutaneously provided rapid, high-grade, limited-duration platelet inhibition while being well tolerated.

    Link to Article

    Q1 2020

    Q1 2020

    Phase 2A study completed

    The open-label, randomized study assessed the onset of platelet aggregation inhibition after a single subcutaneous injection in 27 adults with STEMI just prior to PCI. Zalunfiban provided rapid and potent platelet inhibition, with a return to 50% of platelet function within about two hours.

    Link to Article

    Q2 2021

    Q2 2021

    CeleBrate launches as Phase 2B study

    CeleCor designs a randomized, placebo-controlled clinical trial to study zalunfiban or placebo, subcutaneously injected in STEMI patients treated in ambulances at the first point of contact. The primary endpoints were based on ECG and angiographic outcomes.

    Q1 2022

    Q1 2022

    CeleBrate trial status changed to Phase 3 pivotal clinical trial

    CeleCor modifies CeleBrate’s primary endpoints to a seven-point clinical scale and designates as a Phase 3 pivotal clinical trial after discussion with regulatory agencies.

    Link to Clinical Trial

    Today

    Today

    Phase 3 study

    CeleBrate is now designed as a pivotal Phase 3 prospective, blinded, randomized, placebo-controlled, international, multicenter study designed to assess the safety and efficacy of a single subcutaneous injection of zalunfiban in STEMI patients in the pre-hospital setting.

    Q2 2024

    Q2 2024

    Phase 3 study estimated completion Spring 2024

    CeleBrate: CeleCor’s Phase 3 trial of zalunfiban

    Learn more about CeleBrate

    The future of zalunfiban:

    Additional potential indications

    If zalunfiban is successful in its first indication, there is potential for additional use beyond the medical first responder environment. These include (subject to FDA clearance) potential use at the emergency department and during inter-hospital transfer or transfer from a remote emergency room.

    The combination of an auto-injector for subcutaneous administration and an easy-to-use ECG to diagnose a heart attack potentially make zalunfiban an ideal solution for patient self-administration. This would allow treatment even before a medical first responder arrives.

    ×